AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1535419
Drug: Aspirin before
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin before myocardial infarction
Trial: 1535419
Drug: Aspirin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin after myocardial infarction
Trial: 1535419
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists after myocardial infarction
Trial: 27684533
Drug: weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly paclitaxel
Trial: 20663996
Drug: Argatroban (250,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (250, 300, or 350 µg/kg as bolus before PCI, followed by 15, 20, or 25 µg/kg/min infusion)
Trial: 20663996
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (70-100 IU/kg bolus)
Trial: 11868762
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg tablets b.i.d. for 7 d
Trial: 11868762
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid 1000 mg tablets o.d. for 7 d
Trial: 12515162
Drug: L-HSA-Ara-AMP (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-HSA-Ara-AMP (35 mg/Kg daily for 5 days)
Trial: 7989928
Drug: Preparatory regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparatory regimen consisting of fractionated total-body irradiation (12 Gy total administered in 10 1.2-Gy fractions), etoposide (60 mg/kg), and cyclophosphamide (100 mg/kg).
Trial: 2543553
Drug: Beet-fibre diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beet-fibre diet (mean 40 g FibrexR, 27 g dietary fibre per day)
Trial: 1123455
Drug: Betahistine hydrochloride
RxNorm normalized name: Betahistine Hydrochloride
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine hydrochloride (SERC), 20 mg
Trial: 1123455
Drug: Betahistine hydrochloride
RxNorm normalized name: Betahistine Hydrochloride
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine hydrochloride (SERC), high dosage (16 mg)
Trial: 26403410
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (methylprednisolone aceponat), applied once a day for three months (group A)
Trial: 26403410
Drug: Topical calcineurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcineurin inhibitors (tacrolimus), applied twice a day for three months (group B)
Trial: 23948642
Drug: Risk score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk score based on clinical variables (age, residence, body mass index, on-treatment heart rate and BP, prior myocardial infarction, heart failure, stroke/transient ischemic attack, smoking, diabetes, peripheral arterial disease, chronic kidney disease)
Trial: 21480317
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon and ribavirin therapy
Trial: 16918513
Drug: VLA-4 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: VLA-4 antagonist GW559090X (3 mg)
Trial: 15307010
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg once-daily lamivudine (3TC)
Trial: 15307010
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg twice-daily lamivudine (3TC)
Trial: 15307010
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg twice-daily zidovudine
Trial: 15307010
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg once-daily efavirenz
Trial: 11795863
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy (triple-therapy: Clarithromycin, Amoxicillin, and Omeprazole for one week)
Trial: 9463301
Drug: New allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: New allopurinol formulation (300 mg)
Trial: 9463301
Drug: Reference allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference allopurinol formulation
Trial: 8431665
Drug: Enalapril (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (0.1 mg/kg)
Trial: 26850803
Drug: Lavender essential
RxNorm normalized name: Nature's Truth Lavender Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender essential oil inhalation (5% for 10 min, three times a week for 4 weeks)
Trial: 24225740
Drug: Antioxidant capsule
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant capsule group (AO group)
Trial: 16793163
Drug: Information booklet
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information booklet (the 'back book') and usual physical therapy
Trial: 16793163
Drug: Usual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual physical therapy only with nonstandardized oral information
Trial: 14738126
Drug: Lozenge containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge containing 56.4mg (3 percent w/w) CPP-ACP
Trial: 14738126
Drug: Lozenge containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge containing 18.8mg (1 percent w/w) CPP-ACP
Trial: 14738126
Drug: Lozenge not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge not containing CPP-ACP
Trial: 14738126
Drug: No lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lozenge nil-treatment control
Trial: 2850904
Drug: enalapril 10-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10-20 mg/d
Trial: 2850904
Drug: hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (HCTZ) 12.5-25 mg/d
Trial: 2850904
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy (enalapril + HCTZ)
Trial: 27661661
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow MSCs by intradiscal injection of 25 × 10 cells per segment under local anesthesia
Trial: 23289530
Drug: KPS improvement
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPS improvement during therapy
Trial: 18057912
Drug: Clo‐Met (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clo‐Met (100 mg clotrimazole and 100 mg metronidazole)
Trial: 16931507
Drug: Pramipexole 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.50 mg/day
Trial: 9214527
Drug: Pramipexole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (all doses combined)
Trial: 12656937
Drug: Daily left
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily left prefrontal rTMS (5 Hz, 110% motor threshold, 8 sec on, 22 sec off, over 20 min) for 2 weeks
Trial: 12656937
Drug: Daily left
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily left prefrontal rTMS
Trial: 380367
Drug: Haloperidol 20-35
RxNorm normalized name: haloperidol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 20-35 mg intravenously
Trial: 380367
Drug: Diazepam 30-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 30-40 mg intravenously
Trial: 29029049
Drug: High-remifentanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-remifentanil with naloxone (4 ng ml-1 remifentanil with 0.05 μg kg-1 h-1 naloxone)
Trial: 29029049
Drug: High-remifentanil (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-remifentanil (4 ng ml-1 remifentanil)
Trial: 29029049
Drug: Low-remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-remifentanil (1 ng ml-1 remifentanil)
Trial: 26371617
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) plus treatment-as-usual (TAU)
Trial: 26371617
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral analysis system of psychotherapy (CBASP) plus treatment-as-usual (TAU)
Trial: 21210958
Drug: Intimacy-Enhancing Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intimacy-Enhancing Therapy (IET)
Trial: 16760445
Drug: Ciprofloxacin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (1 g single dose)
Trial: 14757848
Drug: BQ-123 (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (32 microg/min for 120 min) during placebo or insulin clamp
Trial: 11211371
Drug: Fluvoxamine 50
RxNorm normalized name: fluvoxamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 50 to 200 mg/day
Trial: 2656623
Drug: Cefmetazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole (2 g intra-operative iv dose)
Trial: 2656623
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g intra-operative iv dose)
Trial: 4943034
Drug: Penfluridol 30
RxNorm normalized name: penfluridol
DrugBank: Penfluridol (DB13791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penfluridol 30 mg weekly oral dose
Trial: 23690582
Drug: B-vitamin treatment
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin treatment (folic acid 0.8 mg, vitamin B6 20 mg, vitamin B12 0.5 mg)
Trial: 23690582
Drug: B-vitamin treatment
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin treatment
Trial: 21486960
Drug: TBR-652 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBR-652 (25, 50, 75, 100, and 150 mg)
Trial: 16977280
Drug: Gardasil (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil (recombinant quadrivalent human‐papillomavirus‐like particle vaccine)
Trial: 30464407
Drug: Fasted condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted condition (entecavir administration)
Trial: 30464407
Drug: Fed condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed condition (entecavir administration)
Trial: 20231857
Drug: Nicotine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (4 mg as gum)
Trial: 11157665
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide synthesis inhibitor N:(G)monomethyl‐L‐arginine (5.3+/‐1.2%)
Trial: 11157665
Drug: Prolonged episodes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged episodes of reactive hyperemia, hand warming, or incremental infusion of acetylcholine
Trial: 9128028
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 150 micrograms 60-90 min prior to arrival in the operating room
Trial: 3295020
Drug: Lactitol (66.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactitol (66.7 g/100 ml)
Trial: 3295020
Drug: Lactulose (66.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (66.7 ml (44.5 g)/100 ml)
Trial: 31351085
Drug: BoNT &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT & occupational therapy
Trial: 31351085
Drug: BoNT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT therapy alone
Trial: 25793765
Drug: Insulin regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin regimen
Trial: 21872452
Drug: Catecholamine depletion
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catecholamine depletion (CD) using oral alpha‐methyl‐para‐tyrosine
Trial: 19141997
Drug: Paricalcitol treatment
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol treatment under DCa = 3.5 mEq/l
Trial: 19141997
Drug: Paricalcitol treatment
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol treatment under DCa = 3.0 mEq/l
Trial: 19141997
Drug: Paricalcitol treatment
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol treatment under DCa = 2.5 mEq/l
Trial: 11372675
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) (13.0 kDa)
Trial: 11372675
Drug: Medium molecular
RxNorm normalized name: chitosan medium molecular weight (200-800 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium molecular weight heparin (HF) (10.5 kDa)
Trial: 8159637
Drug: 12 IU/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 IU/ml preparation of growth hormone
Trial: 8159637
Drug: 56 IU/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56 IU/ml preparation of growth hormone
Trial: 31193613
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic intravenous hydration
Trial: 26683546
Drug: Emphasis terms
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emphasis terms in warning directives (e.g., 'urgent', 'recommended')
Trial: 26683546
Drug: Emphasis terms
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emphasis terms in warning directives (e.g., 'important', 'compulsory')
Trial: 19317164
Drug: Dannang Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dannang Recipe No. 2 (DNR2) - one dose per day starting from the previous night of operation, composed of various herbal ingredients.
Trial: 19317164
Drug: Ceftizoxime sodium
RxNorm normalized name: Ceftizoxime Sodium
DrugBank: Ceftizoxime (DB01332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftizoxime sodium 2.0 g or Levofloxacin 200 mg via intravenous dripping once 0.5 h before operation and 1-3 days after operation.
Trial: 11707687
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 mg and Enalapril 10 mg
Trial: 11707687
Drug: Nitrendipine 5
RxNorm normalized name: nitrendipine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 5 mg
Trial: 11707687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nitrendipine and enalapril
Trial: 7963143
Drug: Beta-carotene administration
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene administration without a meal
Trial: 7963143
Drug: Beta-carotene administration
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene administration with meals (varied calories and fat)
Trial: 7963143
Drug: Beta-carotene administration
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene administration with high dietary fat
Trial: 7963143
Drug: Beta-carotene administration
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene administration with high caloric content
Trial: 2961357
Drug: Clodronate 400
RxNorm normalized name: clodronic acid 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 400 mg/d
Trial: 2961357
Drug: Clodronate 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1600 mg/d
Trial: 18261100
Drug: Intralesional 5-fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional 5-fluorouracil, lidocaine, and epinephrine (5-FU+LE) - 4 mL of 50 mg/mL 5-fluorouracil and 1 mL of a mixture of 20 mg/mL [2%] lidocaine and 0.0125 mg/mL epinephrine, administered up to four times at weekly intervals.
Trial: 14597516
Drug: Topical aminocaproic
RxNorm normalized name: aminocaproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aminocaproic acid (Caprogel)
Trial: 8635109
Drug: CT +
RxNorm normalized name: Aveeno Protect + Hydrate SPF70 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT + RT (Cisplatin 100mg/m2 on day 1, 5-fluorouracil 1000 mg/m2 from day 1 to 5, followed by RT)
Trial: 3914174
Drug: Recombinant interferon‐alpha‐2C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha‐2C monotherapy
Trial: 31838879
Drug: Standard-of-care (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SC) treatment
Trial: 16221950
Drug: Bee sting
RxNorm normalized name: bee sting kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bee sting therapy (live bees, up to 20, administered three times per week for 24 weeks)
Trial: 16221950
Drug: Bee sting
RxNorm normalized name: bee sting kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bee sting therapy
Trial: 12030735
Drug: Intravenous steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous steroids and aerosol bronchodilators (40 mg methylprednisolone IV, decreasing to 20 mg after 10 days, then 4 mg x 4 days; 10 mg salbutamol and 1 mg ipratropiumbromide aerosol therapy)
Trial: 12030735
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids and MDI bronchodilators (32 mg methylprednisolone orally for 1 week, then 24 mg x day(‐1) for 4 days, decreasing to 4 mg x week(‐1); 1.6 mg fenoterol and 640 microg ipratropiumbromide MDI with a spacer)
Trial: 7741534
Drug: Intravenous enterostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enterostatin (D3800) 4 mg
Trial: 7741534
Drug: Intravenous enterostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enterostatin (D3800) 16 mg
Trial: 29536205
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of dexamethasone orally 1 hour before the procedure
Trial: 29536205
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone orally 1 hour before and 24 hours after the procedure
Trial: 24699466
Drug: Investigational vaccine
RxNorm normalized name: INVESTIGATIONAL VACCINES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational vaccine formulations (10 or 30μg each of dPly and PhtD, alone or in combination with PHiD-CV)
Trial: 24699466
Drug: PHiD-CV (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV (licensed vaccine)
Trial: 24699466
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg dPly/PhtD with PHiD-CV-conjugates
Trial: 24699466
Drug: All pneumococcal
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All pneumococcal protein-containing formulations
Trial: 22432716
Drug: Neurofunctional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofunctional treatment (NFT)
Trial: 18190664
Drug: Buprenorphine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine maintenance treatment
Trial: 12426274
Drug: Informed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Informed administration of the Chronic Respiratory Questionnaire (CRQ)
Trial: 12426274
Drug: Informed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Informed administration of the St. George's Respiratory Questionnaire (SGRQ)
Trial: 12426274
Drug: Blind administration
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind administration of the CRQ
Trial: 12426274
Drug: Blind administration
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind administration of the SGRQ
Trial: 795610
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg indomethacin twice daily
Trial: 30882524
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent epidural boluses (6-mL every 45 minutes of 0.1% ropivacaine with 2 µg/mL fentanyl)